We are live on ! Find out more
ALZN icon

Alzamend Neuro

24 hedge funds and large institutions have $2.7M invested in Alzamend Neuro in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

380% more call options, than puts

Call options by funds: $96K | Put options by funds: $20K

0% less ownership

Funds ownership: 0.01%0% (-0%)

23% less funds holding

Funds holding: 3124 (-7)

33% less capital invested

Capital invested by funds: $4.04M → $2.7M (-$1.34M)

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

88% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 8

Holders
24
Holders Change
-7
Holders Change %
-22.58%
% of All Funds
0.38%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
1
Increased
4
Reduced
6
Closed
8
Calls
$96K
Puts
$20K
Net Calls
+$76K
Net Calls Change
-$93K
Name Holding Trade Value Shares
Change
Change in
Stake
Commonwealth Equity Services
26
Commonwealth Equity Services
Massachusetts
$7
HF
27
HRT Financial
New York
-$32K -42 Closed
Renaissance Technologies
28
Renaissance Technologies
New York
-$28K -37 Closed
E
29
Ergoteles
New York
-$13.3K -17 Closed
Two Sigma Investments
30
Two Sigma Investments
New York
-$10.9K -14 Closed
FWA
31
Freedom Wealth Alliance
Wisconsin
-$8.47K -11 Closed
GSC
32
Ground Swell Capital
South Carolina
-$7.69K -10 Closed
SG
33
StoneX Group
New York
-$6.22K -8 Closed
MCC
34
Money Concepts Capital
Florida
-$141

ALZN Hedge Fund Activity: Q1 2023 in Review

24 of the 6,277 institutional investors tracked by Wall St. Rank reported a position in Alzamend Neuro (ALZN) for Q1 2023, worth a combined $2.7M — down 33% from $4.04M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of ALZN and 1 opened new positions — a net loss of 7 holders — while 6 trimmed existing stakes and 4 added.

The largest buyer was Tower Research Capital (TRC), adding an estimated $6.77K. The largest seller was Vanguard Group, cutting an estimated $310K.

  • 24 institutional investors held Alzamend Neuro (ALZN) as of Q1 2023, down from 31 in Q4 2022.
  • Funds reported $2.7M of Alzamend Neuro stock for Q1 2023, down 33% quarter-over-quarter.
  • 1 fund opened new Alzamend Neuro positions in Q1 2023 and 8 closed out, a net change of -7 holders.
  • The largest Alzamend Neuro buyer in Q1 2023 was Tower Research Capital (TRC), an estimated $6.77K added.
  • The largest Alzamend Neuro seller in Q1 2023 was Vanguard Group, an estimated $310K sold.

Based on aggregated 13F filings for Q1 2023.